Please login to the form below

Not currently logged in
Email:
Password:

Israel's IP war of words

The Israeli government's minister of industry, trade and Labour, Eli Yishai, strongly denies accusations from Teva Pharmaceuticals that he is seeking to change the Intellectual Property Law in the region

The Israeli government's minister of industry, trade and Labour, Eli Yishai, has strongly denied accusations from generic drug manufacturer Teva Pharmaceuticals that he is seeking to change the Intellectual Property Law in the region.

Teva has accused Yishai of considering giving better terms for multinational pharmaceutical companies at the expense of domestic generic drug companies.

In a press statement, Yishai said: "I have not yet made up my mind. The process has only just begun, and I reject all attempts by Teva to influence the decision through the media."

The current argument concerns the expiry of drug patents and the development, production, and marketing of generic equivalents in Israel and their export to other countries. A second issue is how much the Ministry of Health can assist Israeli companies with information about drugs made by multinational pharmaceutical companies.

Yishai met officials of the US Trade Representative (USTR) and representatives of several Israeli pharmaceutical companies in October 2007. Later, a number of delegations of multinational pharmaceutical companies visited Israel, with Merck KGaA signing a memorandum of understanding (MOU) to invest in Israel start-ups.

According to local media reports, Yishai said that changing the IP Law would encourage more multinational pharmaceutical companies to invest in Israel. But Yishai denies promised anything to the foreign companies at the meeting.

Yishai has been accused of ordering the establishment of the inter-ministerial team to review the patent law. Representatives from the Ministries of Finance, Health, Justice, and Industry will participate.

Both Teva and the Ministry of Health claim that the purpose of the committee is to change the law.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics